5IGL

Crystal structure of the second bromodomain of human TAF1L in complex with bromosporine (BSP)


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.1 Å
  • R-Value Free: 0.294 
  • R-Value Work: 0.211 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia.

Picaud, S.Leonards, K.Lambert, J.P.Dovey, O.Wells, C.Fedorov, O.Monteiro, O.Fujisawa, T.Wang, C.Y.Lingard, H.Tallant, C.Nikbin, N.Guetzoyan, L.Ingham, R.Ley, S.V.Brennan, P.Muller, S.Samsonova, A.Gingras, A.C.Schwaller, J.Vassiliou, G.Knapp, S.Filippakopoulos, P.

(2016) Sci Adv 2: e1600760-e1600760

  • DOI: 10.1126/sciadv.1600760
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Bromodomains (BRDs) have emerged as compelling targets for cancer therapy. The development of selective and potent BET (bromo and extra-terminal) inhibitors and their significant activity in diverse tumor models have rapidly translated into clinical ...

    Bromodomains (BRDs) have emerged as compelling targets for cancer therapy. The development of selective and potent BET (bromo and extra-terminal) inhibitors and their significant activity in diverse tumor models have rapidly translated into clinical studies and have motivated drug development efforts targeting non-BET BRDs. However, the complex multidomain/subunit architecture of BRD protein complexes complicates predictions of the consequences of their pharmacological targeting. To address this issue, we developed a promiscuous BRD inhibitor [bromosporine (BSP)] that broadly targets BRDs (including BETs) with nanomolar affinity, creating a tool for the identification of cellular processes and diseases where BRDs have a regulatory function. As a proof of principle, we studied the effects of BSP on leukemic cell lines known to be sensitive to BET inhibition and found, as expected, strong antiproliferative activity. Comparison of the modulation of transcriptional profiles by BSP after a short exposure to the inhibitor resulted in a BET inhibitor signature but no significant additional changes in transcription that could account for inhibition of other BRDs. Thus, nonselective targeting of BRDs identified BETs, but not other BRDs, as master regulators of context-dependent primary transcription response.


    Organizational Affiliation

    Structural Genomics Consortium, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, U.K.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Transcription initiation factor TFIID subunit 1-like
A
155Homo sapiensMutation(s): 0 
Gene Names: TAF1L
Find proteins for Q8IZX4 (Homo sapiens)
Go to Gene View: TAF1L
Go to UniProtKB:  Q8IZX4
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
BMF
Query on BMF

Download SDF File 
Download CCD File 
A
Bromosporine
ethyl (3-methyl-6-{4-methyl-3-[(methylsulfonyl)amino]phenyl}[1,2,4]triazolo[4,3-b]pyridazin-8-yl)carbamate
C17 H20 N6 O4 S
UYBRROMMFMPJAN-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.1 Å
  • R-Value Free: 0.294 
  • R-Value Work: 0.211 
  • Space Group: I 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 44.172α = 90.00
b = 89.177β = 90.00
c = 117.892γ = 90.00
Software Package:
Software NamePurpose
XDSdata reduction
SCALAdata scaling
REFMACrefinement
PHASERphasing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2016-10-19
    Type: Initial release
  • Version 1.1: 2016-11-02
    Type: Database references